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The Escherichia coli K5 capsular polysaccharide has 
the same (GlcUA->GlcNAc)n structure as the nonsul­
fate d heparan sulfate/heparin precursor polysaccha­
ride. A monoclonal antibody (mAb 865) against the K5 
polysaccharide has been described (Peters, H., Jiirs, M., 
Jann, B., Jann, K., Timmis, K. N., and Bitter-Sauermann, 
D. (1985) Infect. Immun. 50, 459—466). In this report, we 
demonstrate the binding of anti-K5 mAb 865 to N-acety- 
lated sequences in heparan sulfates and heparan sulfate 
proteoglycans but not to heparin. This is shown by di­
rect binding and fluid phase inhibition of mAb 865 in an 
enzyme-linked immunosorbent assay. In this system we 
found that the binding of the mAb decreased with in­
creasing sulfate content of the polysaccharide. By test­
ing chemically modified K5 and heparin polysaccha­
rides, we found that each of the modifications that occur 
during heparan sulfate (HS) synthesis (iV-sulfation, C-5 
epimerization, and O-sulfation) prevents recognition by 
mAb 865. Samples of heparan sulfate from human aorta 
(HS-II) were selectively degraded so as to allow the sep­
arate isolation of iV-sulfated and 2V-acetylated block 
structures. JV-Sulfated oligosaccharides (obtained after 
iV-deacetylation by hydrazinolysis followed by nitrous 
acid deamination at pH 3.9) were not recognized by mAb 
865, in contrast to iV-acetylated oligosaccharides (ob­
tained after nitrous acid deamination at pH 1.5), al­
though the reactivity was lower than for intact HS-II. 
Analysis of the latter’s pH 1.5 deamination products by 
gel filtration indicated that a minimal size of 18 saccha­
ride units was necessary for antibody binding. These 
results lead us to propose bivalent antibody-heparan 
sulfate interaction, in which both F(ab) domains of the 
mAb interact with their epitopes, both of which are 
present in a single large (£:18 saccharide units) iV-acety- 
lated domain and additionally with single epitopes pres­
ent in two iV-acetylated sequences (each < 18 saccharide
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units) bridged by a short iV-sulfated domain. Immune* 
histochemistry with mAb 865 on cryostat sections of 
normal human kidney tissue, revealed its binding to 
most but not all renal basement membranes. However, 
all renal basement membranes contain heparan sulfate, 
as shown by a mAb against heparitinase-digested hepa­
ran sulfate stubs (mAb 3G10). This finding indicates that 
not all heparan sulfate chains present in basement mem­
branes express the mAb 865 epitopes. Besides the nor­
mal distribution, mAb 865 staining was found in fibrotic 
and sclerotic lesions in vessels, interstitium, and mesan- 
gium in transplant kidneys with chronic vascular rejec­
tion. Occasionally, a decrease of staining was observed 
within tubulo-interstitium and glomeruli. These find­
ings show that iV-acetylated sequences in heparan sul­
fates can be demonstrated by anti-K5 mAb 865 in normal 
and diseased kidneys.
The biosynthesis of heparan sulfate (HS)1 involves the forma­
tion of a nonsulfated (GlcUA/31,4->GlcNAcal,4)„ precursor po­
lysaccharide AT-acetylheparosan, which subsequently undergoes 
a series of polymer modification reactions. These reactions start 
with N-deacetylation/N-sulfation of GlcNAc residues, which is 
followed by C-5 epimerization of GlcUA to Idee A units, and fi­
nally by O-sulfation at various positions (1). The GlcUA C-5 
epimerization and O-sulfation reactions occur in the close vicinity 
of iV-sulfate groups, pointing to a key role for the glucosaminyl 
AMeacetylase/A^sulfotransferase enzyme in determining the 
overall extent of modification of the HS chain. Structural analy­
sis of HS from various sources has revealed that these modifica­
tions tend to colocalize in block sequences, separated by rela­
tively unmodified domains (2-6). The extent of biosynthetic 
modification, affecting the number, length, and substitution pat­
terns of the modified domains as well as their position along the 
HS chain, may differ among cell types (7), alter during prolifer­
ation (8), and change as a result of cell transformation (9,10).
Many biological activities of heparan sulfate proteoglycans 
(HSPGs) are due to interactions between the HS polysaccha­
ride side chains and a variety of proteins such as extracellular 
matrix molecules, enzymes, enzyme inhibitors, growth factors, 
and other cytokines (1,11-13), These interactions can be either 
specific, dependent on defined sulfation patterns within given 
sequences of sugar residues, as described for antithrombin (14),
1 The abbreviations used are: HS, heparan sulfate(s); ELISA, en­
zyme-linked immunosorbent assay; HSPG, heparan sulfate proteogly- 
can(s); mAb, monoclonal antibody; PBS, phosphate-buffered saline.
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basic fibroblast growth factor (15,16), hepatocyte growth factor 
(17), and interferon-7 (18); or they can be mainly based on 
relatively nonspecific electrostatic interactions and involve pro­
teins such as lipoprotein lipase (19), platelet factor 4 (20) and 
mast cell protease I (2 1 ) (see Ref. 22 for a general discussion).
Structural analysis of HS is complicated by the fact that even 
highly purified and uniform preparations consist of mixtures of 
polysaccharide chains that have reached different levels of 
modification. Monoclonal antibodies (mAbs) that specifically 
recognize well-defined epitopes in HS could be major tools in 
such analysis. Already in 1985 a mAb (designated as mAb 865) 
against the Escherichia coli K5 polysaccharide had been de­
scribed (23). This bacterial polysaccharide has the same 
(GlcUA/31,4—>GlcNAcal,4)/z structure as the nonsulfated HS/ 
heparin precursor polysaccharide (24), suggesting that anti-K5 
mAb 865 might recognize the iV-acetylated (K5-like) domains 
in HS. In the present report, we show that this is indeed the 
case. Immunohistological application of the mAb on normal 
human renal tissue and on transplant kidneys with chronic 
vascular rejection revealed these iV-acetylated HS sequences in 
extracellular matrix and basement membranes. Since in most 
protein-HS interactions highly sulfated, IdceA-rich domains 
are involved, the possible biological significance of these rela­
tively unmodified iV-acetylated domains in HS is discussed.
MATERIALS AND METHODS
Glycosaminoglycans and Heparan Sulfate Proteoglycans ~  HS (prep­
aration HS-II) was isolated from human aorta, essentially according to 
Iverius (25). HS from pig intestine, the E, coli K5 capsular polysaccha­
ride, with the same (GlcUA—>GlcNAc),t structure as the nonsulfated 
HS/heparin precursor polysaccharide (24) and chemically O-sulfated K5 
polysaccharide were kindly provided by Dr. G. van Dedem (Organon 
Corp., Oss, The Netherlands). iV-Sulfated K5 was given by Dr. B. Casu 
(Instituto di Chimica e Biochimica G. Ronzoni, Milan, Italy). Intact 
heparin (stage 14) from pig intestinal mucosa was obtained from Inolex 
Pharmaceutical Division (Park Forest South, IL) and purified by re­
peated precipitation with cetylpyridinium chloride from 1.2 M NaCl 
(26). Heparan sulfate proteoglycans were isolated from the mouse En- 
gelbreth-Holm-Swarm sarcoma (Becton Dickinson Labware, Bedford, 
MA) or from ra t glomerular basement membranes, essentially accord­
ing to van den Heuvel et al. (27). Briefly, glomeruli were isolated from 
ra t kidney cortex by a sieving method. Glomerular basement mem­
branes were isolated from glomeruli by the detergent method, extracted 
twice in 4 M guanidine and dialyzed against 7 M urea, and HSPG was 
isolated by ion exchange chromatography. HSPG containing fractions 
were pooled, concentrated, and extensively dialyzed against phosphate- 
buffered saline (PBS).
Chemical Modifications o f Polysaccharides-N -Acetylated oligosac­
charides were derived from HS-II by low pH nitrous acid deamination, 
Reaction at pH 1.5 (10 min) was performed as described (28) and 
resulted in selective attack of iV-sulfated GlcN units, with cleavage of 
the corresponding glucosaminidic linkages (29). The deamination prod­
ucts were reduced with NaBH4. Deamination products, obtained after 
degradation of 3 mg of HS-II by nitrous acid, pH 1.5 followed by 
reduction with NaBH4 were analyzed by gel chromatography on a 
column (1 X 140 cm) of Bio-Gel P-10 fine (Bio-Rad Laboratories, Her­
cules, CA) in 0.5 M ammonium hydrogen carbonate, eluted at a rate of
2.4 ml/h. Effluent fractions of 0.6 ml were collected and analyzed for 
hexuronic acid by the carbazole reaction (30), lyophilized twice to get rid 
of the ammonium hydrogen carbonate, dissolved in PBS, and tested in 
the inhibition ELISA for mAb 865 binding (see below). To obtain N- 
sulfated oligosaccharides, HS-II was deacetylated by hydrazinolysis 
followed by deamination at pH 3.9 (31). For JV-deacetylation by hydrazi- 
nolysis, samples (1 mg) of HS-II were dissolved in 1 ml of hydrazine 
hydrate (Fluka; H20  content, 36%) containing 1% (w/v) hydrazine sul­
fate and heated in sealed glass tubes at 96 °C. After 4 h, the samples 
were repeatedly evaporated to dryness and desalted on PD-10 columns 
(Pharmacia, Uppsala, Sweden) according to the instructions of the 
manufacturer. After this procedure, deamination at pH 3.9 (28) cleaved 
the polysaccharide chain at A^-unsubstituted GlcN residues (29). The 
deamination products were reduced with NaBH4. Completely (N- and
0-) desulfated heparin was prepared according to Jacobsson et al. (32), 
and iV-acetylated by treatm ent with acetic anhydride as described by
Danishefsky et al. (33).
ELISA—Binding properties of mAb 865 to polysaccharides were 
tested in ELISA. Polysaccharides (50 pig/ml) were coated overnight at 
room temperature in PBS to the wells of polystyrene flat-bottom micro - 
titer plates (NUNC Maxisorp, Life Technologies, Inc., Breda, The N eth­
erlands), 100 /xlAvell. Alternatively, HSPG (1 ¿xg/ml) was coated under 
the same conditions. Wells were washed 6 times with PBS containing
0.05% Tween 20 (PBS-T) and incubated for 2 h at room temperature 
with PBS containing 1% gelatin, 120 ¿d/well, to avoid nonspecific anti­
body binding. After washing again with PBS-T, a dilution range of mAb 
865 in PBS-T, 100 juJ/well, was incubated for 1 h at room temperature 
in the ELISA plates. Detection of the mAb and substrate reaction was 
identical to the inhibition ELISA and has been described before (34). 
The mAb 865 inhibition ELISA is based on the inhibition of mAb 865 
binding to coated K5 or HS-II by liquid phase polysaccharides, HS-II- 
derived oligosaccharides, or intact HSPGs, Percentage of inhibition was 
calculated as (1 -  (A450 with inhibit or/A450 without inhibitor)) x 
100%. IC50 (/xg of inhibitor/ml) is defined as the concentration of inhib­
itor that gives 50% inhibition in the ELISA system.
Immunohistology—Normal human kidney specimens in = 8) were 
obtained during surgery or were from cadaveric donor kidneys not 
suitable for transplantation. Specimens of renal transplant tissue (n = 
8) were obtained by percutaneous biopsy or after nephrectomy of the 
renal graft. Indirect immunofluorescence analysis was performed as 
described (35) on 2-ju.m human kidney cryostat sections. The antibodies 
used were a mouse IgM mAb against the E. coli K5 capsular polysac­
charide, which has been described before (23), and the mouse IgG2b 
mAb 3G-10, reacting with HS stubs generated by heparitinase digestion 
(36) (a gift from Dr. G. David, University of Leuven, Belgium). Hep­
aritinase (Sigma, EC 4.2.2.8) digestion of the sections was done for 1 h 
at 37 °C, 0.25 units/ml in 10 mM HEPES buffer containing 1 mM Ca2+, 
pH 7.0. As secondary antibodies, fluorescein isothiocyanate-labeled 
goat anti-mouse IgM (Fc) (Nordic, Tilburg, The Netherlands), and flu­
orescein isothiocyanate-labeled F(ab)2 fragments of sheep anti-mouse 
IgG (Organon Teknika, Turnhout, Belgium) were used. Control exper­
iments in which the fluorescein isothiocyanate-labeled secondary anti­
bodies were applied to the sections without prior primary antibody 
incubation were consistently negative. mAb 3G10 was completely neg­
ative without pretreatment of the sections with heparitinase. Sections 
were embedded in Vectashield (Vector Laboratories Inc., Burlingame, 
CA) and examined on a Zeiss Axioskop microscope equipped for fluo­
rescence microscopy.
RESULTS
Expression of the Anti-K5 mAb 865 Epitope in Heparan S u l­
fates and Heparan Sulfate Proteoglycans — The binding of the 
anti-K5 mAb 865 to HS was tested in ELISA with a low sul- 
fated HS preparation (—0.6 sulfate groups/disaccharide; iso­
lated from human aorta, designated as HS-II), a high sulfated 
HS preparation (—1.5 sulfate groups/disaccharide; isolated 
from porcine intestine), and heparin (—2.5 sulfate groups/di- 
saccharide), and compared with the binding to the nonsulfated 
K5 polysaccharide. From Fig. 1A it becomes clear that HSs are 
recognized by the mAb, especially the low sulfated HS-II, al­
though to a lesser extent than the K5 polysaccharide. The mAb 
did not bind to heparin. Since the coating efficiency of these 
polysaccharides might be unequal due to differences in nega­
tive charge, we tested the same preparations in a fluid phase 
inhibition ELISA. HS-II was used to coat the ELISA plates. 
Results are shown in Fig. IB and are essentially the same as 
found in the direct ELISA (Fig. 1 A). The inhibitory activity of 
HS-II was ± 3000-fold lower than that of K5. Since high sul­
fated HS demonstrated only weak inhibition and heparin did 
not inhibit at all, it is suggested that the extent of chain 
modification is inversely correlated with antibody binding.. In 
control experiments mAb 865 was tested for its binding to other 
glycosaminoglycans such as chondroitin sulfate A and C, der- 
matan sulfate, and hyaluronic acid and to dextran sulfate and 
DNA, which all were completely negative. These control exper­
iments exclude the possibility that the binding of mAb 865 to 
HS is due to nonspecific, charge-based interactions.
Next to glycosaminoglycans, the mAb was also tested for 
binding to isolated HSPG from mouse Engelbreth-Holm- 
Swarm sarcoma (perlecan) and from ra t glomerular basement
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inhibitor in  the inhibition ELISA (B and D).
membranes. Both HSPGs were recognized by mAh 865 in the 
direct ELISA and as fluid phase inhibitor (Fig. 1 , C and D), 
Engelbreth-Holm-Swarm HSPG expressing more mAb 865 
epitopes/mg core protein than glomerular basement membrane
HSPG.
Heparitinase digestion of the HSPGs abolished all binding of 
mAb 865, whereas the binding of antibodies against the core 
proteins of both HSPGs were not affected by this treatment 
(not shown), thereby confirming HS specificity of mAb 865.
R ecognition  o f  C hem ically M odified K 5  a n d  H eparin  Polysac­
charides by m A b  8 6 5 —HS differs in three major regards from 
K5: (i) iV-sulfation of GlcN units, (ii) C-5 epimerization of hexu- 
ronate residues, and (iii) O-sulfation at different positions. To 
investigate whether the epitope requirements in HS and K5 
are identical, the effect of chemical modification of the K5 
polysaccharide on antibody binding was studied in the inhibi­
tion ELISA with K5 as coated antigen (Table I). Complete 
iV-sulfation of K5 abolished all binding to the mAb. To evaluate 
the effect of C-5 epimerization we tested completely (N- and 0-) 
desulfated, AT-reacetylated heparin. This preparation differs 
from K5 in one major regard, i.e. the occurrence of IdceA units 
(±80% of the total hexuronic acid contents). From Table I it is 
inferred that such units completely prevent antibody binding. 
We also tested an O-sulfated K5 polysaccharide preparation 
containing an average of —1.2  O-sulfate (but no JV-sulfate) 
groups/disaccharide unit. The locations of the O-sulfate groups 
were not defined but would presumably primarily involve C-6 
of the GlcN units, along with C-2 and/or C-3 of the GlcUA units.
The results in Table I clearly show that O-sulfation of K5 
polysaccharide completely prevents mAb 865 binding. From 
these experiments we concluded that each of the modifications 
known to occur during HS synthesis (iV-sulfation, C-5 epimer­
ization, and O-sulfation) prevents recognition by anti~K5 mAb 
865.
R equirem ents o f  the m A b  865 E pitopes in  the H S  C ha in  — In 
order to define the requirements of the mAb 865 epitopes in the 
HS chain more precisely, samples of HS-II were selectively 
degraded to isolate separately N-sulfated and N-acetylated 
block structures of the molecule (see “Materials and Methods”). 
These oligosaccharides were then tested in the mAb 865 inhi­
bition ELISA using HS-II as coated antigen. The results in Fig. 
2 demonstrate complete loss of reactivity for the N -sulfated 
oligosaccharides. In contrast to this, the Af-acetylated oligosac­
charides are still recognized by mAb 865, although to a consid­
erably lower extent. Nitrous acid degradation at pH 3.9 alone,
i.e. not preceded by iV-acetylation, had no influence on antibody 
binding, which indicates that iV-unsubstituted GlcN units are 
not located within the epitopes. In this respect, anti-K5 mAb 
865 clearly differs from another anti-HS mAb (JM-403) that we 
described recently, whose epitope is dependent on the presence 
of N-unsubstituted glucosamine units in HS (37). The fact that 
the heavily modified, heparin-like A^-sulfated block sequences 
of the HS chains (obtained after nitrous acid deamination at pH 
3.9 of N-deacetylated HS-II) lacked all mAb 865 binding sug­
gests to us that the epitope is located in the N-acetylated 
regions of HS. If this is true, why is there a considerable loss of
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Ta b l e  I
Concentration of native K5, chemically modified K5 and heparin derivatives giving 50% inhibition in the ELISA system
K5 or heparin derivative Characteristic IC 5Û
Native K5 
JV-Sulfated K5
7^,0-Desulfated, iV-reacetylated heparin 
0 -Sulfated K5
100% (l,4GlcA~^l,4GlcNac)„, no sulfation, no IdceA units
All GlcN units are sulfated, no O-sulfates
No sulfation, ±80% IdceA units
1.2 O-sulfate groups/disaccharide, no iV-sulfates
Hg/ml
0.4
>100
>100
>100
c
o
- C
c
Inhibitor (ng/ml)
F ig .  2. Fluid phase inhibition of mAb 865 binding to HS-II from 
human aorta by HS-II-derived oligosaccharides. Inhibition was
performed with native HS-II ( • -----• ) ,  N-sulfated oligosaccharides of
HS-II (isolated after JV-deacetylation by hydrazinolysis followed by
deamination a t pH 3.9; ♦ -----♦), iV-acetylated oligosaccharides of
HS-II (isolated after deamination a t pH 1.5; O-----O); HS-II treated
with nitrous acid at pH 3.9 alone, i.e. not preceded by JV-deacetylation 
(+ -----+).
inhibitory capacity of the iV~acetylated domains, which are 
obtained after nitrous acid pH 1.5 cleavage of HS? From the 
work of others we know that a size of five sugar residues is 
sufficient for monovalent antibody binding (38). Therefore, we 
analyzed the minimal binding size of iV-acetylated oligosaccha­
rides derived from HS-II, which still demonstrate binding to 
the mAb. To this end, a 3-mg sample of HS-II was deaminated 
by nitrous acid, pH 1,5. The resulting oligosaccharides were 
subsequently separated by gel filtration on a Bio-Gel P-10 
column. From Fig. 3 it becomes clear that only large, A^acety- 
lated oligosaccharides >18 residues bound to mAb 865, This 
finding suggests that bivalent epitope recognition is required 
for adequate binding of the mAb,
Immunohistology with mAb 865 on Normal Human Renal 
Tissue—The epitopes detected by mAb 865 in cryostat sections 
of human renal tissue were expressed in most but not all 
basement membranes in a linear fashion. Glomerular base­
ment membranes were moderately positive, while Bowman's 
capsule and mesangial matrix were more prominent (Fig. 4A). 
Basement membranes of endothelial cells of peritubular capil­
laries and other blood vessels, including the basal laminae 
surrounding vascular smooth muscle cells were strongly posi­
tive (Fig. 4C). Tubular basement membrane staining varied 
from strongly positive to completely negative (Fig. 4, A and C). 
In two kidney specimens of older patients moderate interstitial 
fibrosis and mesangial matrix accumulation were found, which 
were stained with mAb 865 (not shown). HS specificity of the 
staining was demonstrated by pretreatment of the sections 
with heparitinase, which completely prevented all staining (not 
shown). On the other hand, all renal basement membranes 
were stained by mAb 3G10, which reacts with the residual HS 
stubs remaining after enzymatic cleavage by heparitinase (Fig. 
4, B  and D). The resultant 3G10 epitope contains an essential,
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Fig. 3. mAb 865 recognition of pH 1.5 deamination products of 
HS-II. A 3-mg sample of HS-II was subjected to nitrous acid degrada­
tion at pH 1.5 followed by gel filtration of the fragments on a  Bio-Gel 
P-10 fíne column as described under “Materials and Methods.” Effluent 
fractions were analyzed for hexuronic acid by the carbazole reaction
(panel A f A  530, • -----• )  and for mAb 865 reactivity in the inhibition
ELISA (panel B , percentage of inhibition, O-----O). The number of
monosaccharides of the separated oligosaccharides is indicated at the 
top of each peak in panel A. The column was calibrated by dextran blue 
(V0) and aH-labeled heparin disaccharides.
terminal, 4,5-unsaturated uronate residue and thus can serve 
as a general HS marker, of which staining intensity is inde­
pendent of HS modifications (36). These results demonstrate 
the presence of HS in all renal basement membranes, some of 
them being negative for the mAb 865 epitope. The most likely 
explanation points toward differences in modification/sulfation 
of HS in the various basement membranes, highly modified HS 
being negative and low sulfated HS being positive for mAb 865.
Distribution of mAb 865 Epitopes in Transplant Kidneys 
with Chronic Vascular Rejection—Since we observed in some 
normal kidney biopsies that interstitial and periglomerular 
fibrosis and mesangial sclerosis were associated with a higher 
binding of mAb 865, we analyzed renal transplant biopsies 
with chronic vascular rejection. Chronic vascular rejection in 
kidney transplants is morphologically characterized by severe 
narrowing of arteries due to intima fibrosis and interstitial 
fibrosis with tubular atrophy. Sometimes a glomerulopathy,
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value agrees with the calculated distance between both Fab 
arms of an immunoglobulin molecule (39). Simultaneous bind­
ing of both F(ab) antibody domains will strongly promote the 
interaction. It is noteworthy that a comparable type of bivalent 
binding has been described recently for the interaction of in- 
terferon-y dimer with HS (18). In this elegant study it was 
shown that the high affinity binding domain for interferon-7 in 
HS is composed of two terminal iV-sulfated domains, linked 
together by an intervening iV-acetylated domain. The interfer- 
on~y dimer bound to both iV-sulfated terminal regions, while a 
monovalent interferon-y-HS interaction was insufficient for 
stable binding. Our finding that deamination at pH 1.5 results 
in partial loss of antibody recognition suggests that in native 
HS, not only the large Af-acetylated domains (S:18 saccharide 
units) but also smaller N-acetylated sequences bridged by a 
short iV-sulfated domain, are recognized by mAb 865. Cleavage 
of the HS polysaccharide at iV-sulfated glucosamine residues 
(deamination a t pH 1.5) thus abolishes bivalent antibody rec­
ognition of such small iV-acetylated sequences. Alternatively, 
the extended minimal polymer size of 18 saccharide units 
needed for antibody recognition might be explained by assum­
ing a conformational epitope. For example, in a helical polymer 
structure, a much longer primary sequence will be required for 
the maintenance of a conformational epitope.
Immunofluorescence studies on human kidney sections with 
mAb 865 revealed tha t the carbohydrate epitope is not evenly 
distributed among the HS subspecies of this tissue. All base­
ment membranes, as expected, were found to contain HS, as 
evidenced by the anti-HS stub mAb 3G10. However, the po­
lysaccharide present in some tubular basement membranes 
stained poorly with mAb 865, suggesting the existence of HS 
isoforms lacking the corresponding epitope. The most likely 
explanation for this is the existence of a high sulfated HS 
isoform in these particular tubular basement membranes. This 
is supported by the finding that another anti-HS mAb (JM- 
403), which recognizes epitopes with JV-unsubstituted glucosa­
mine units in low sulfated HS isoforms (37), shows the same 
staining pattern. Alternatively, the N-acetylated domains may 
be inappropriately spaced for antibody binding. Staining with 
mAb 865 was also observed in mild fibrosis and sclerosis, which 
is found in normal renal tissue, secondary to aging. This led us 
to the analysis of renal tissue with more extensive fibrosis. To 
this end we evaluated renal transplant biopsies with chronic 
vascular rejection. In these biopsies, fibrotic and sclerotic le­
sions were positive for both anti-HS stub mAb 3G10 and for 
mAb 865. This increased staining, however, is not specific for 
vascular chronic rejection, since preliminary experiments in 
our laboratory indicated that also in experimental models of 
renal diseases (Adriamycin nephropathy and active Heymann 
glomerulonephritis), fibrotic areas clearly express the mAb 865 
epitope.2 Using anti-K5 mAb 865 as a probe to detect HS, our 
findings indicate that HS in these fibrotic/sclerotic areas rep­
resents a low sulfated HS isoform. We suggest that these HS 
chains are attached to perlecan, since anti-perlecan core pro­
tein mAbs also stain renal fibrotic/sclerotic areas (40), and mAb 
865 binds to perlecan in ELISA (Fig. 1 , C and D ).
What is the biological significance of these Af-acetylated do­
mains in HS? As indicated in the Introduction, many growth 
factors, enzymes, and enzyme inhibitors can bind to HS. Gen­
erally such interactions involve variously sulfated regions 
along the polysaccharide chain; so far no proteins have been 
shown to specifically interact with the N- acetyl ate d domains in 
HS. Nevertheless, N-acetylated sequences in HS have been 
implicated in a variety of biologically important processes.
2 C. J. I. Raats and J. van den Born, unpublished observations.
Thus, JV- acetyl ate d oligosaccharides isolated after nitrous acid 
deamination of HS from bovine lung were found to be more 
effective inhibitors of m esangial cell proliferation than  either  
the intact polymer or highly sulfated oligosaccharides from the  
same source (41). Moreover, it has been shown th at HS frag­
m ents obtained after digestion w ith heparinase (yielding low  
sulfated GlcUA- and GlcNAc-rich oligosaccharides) inhibited  
endothelial cell proliferation induced by acidic fibroblast 
growth factor, in contrast to HS fragm ents obtained after di­
gestion with heparitinase (yielding high sulfated IdceA-rich 
oligosaccharides) (42). Moreover, it has been reported that 
sm all K5 fragments and N -acetylated oligosaccharides derived 
from HS inhibited normal angiogenesis (43). These data indi­
cate that mAb 865-positive HS present in the extracellular  
matrix may represent a pool of immobilized precursors of an­
tiproliferative and antiangiogenic oligosaccharides. It has been  
demonstrated that biologically active oligosaccharides m ay be 
released from the m atrix by the action of various endoglycosi- 
dases (44 -48 ). While the substrate specificities of these en­
zymes have not yet been elucidated in detail, it has been  
suggested that certain enzym e species m ay preferentially  
cleave nonsulfated regions in the HS chain (49), w hereas others 
require sulfate groups for substrate recognition (50 -52). We 
thus may envisage an elaborate system  of distinct bioactive 
oligosaccharides, generated by the action of endoglycosidases 
on HS substrates composed of sulfated and nonsulfated  
regions.
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